Totally agreed, although adding a few more events as they are petitioning the FDA to do from 92 to 109 or whatever might delay the interim by maybe a month to six weeks. Once patents 'fail' on Avastin, i.e. stop responding, there is a steep ascent with rapid death which is why prior Avastin use is not allowed in the trial.
So, there should be a rapid increase in event in the second and third quarters of '17. 2017 will definitely be the year.
News 
Market Data 
Discover 
